Clinical Trial: Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487597) titled 'Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors' on March 17.

Brief Summary: This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of functionally enhanced ALPP-targeted engineered T Cells (Herein referred to as Enhanced ALPP CAR-T) in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.

Study Start Date: Feb. 28 ...